β-CATENIN/T-CELL FACTOR (TCF) FOR TARGETING CANCER AND IMMUNE TOLERANCE

Irregular activation of the Wnt/β-catenin pathway leads to initiation and progression of many cancers, such as colorectal cancer, leukemia, and multiple myeloma. Cancer stem cells, which are resistant to conventional therapies, are also controlled by Wnt signaling. Recent studies indicate Wnt/β-catenin signaling provides therapeutic benefits as a molecular switch between opposing immune functions to treat autoimmune diseases, cancer, and infectious diseases.

The proposed technology describes design and synthesis of micro-molar inhibitors of β-catenin/Tcf inhibitors with outstanding selectivity, suitable for additional drug development.